• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers

Cardio3 BioSciences to address American institutional investors in January at J.P. Morgan Healthcare Conference

December 15, 2014 By Celyad

Mont-Saint-Guibert, Belgium – Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the development of regenerative therapies, announces its participation to the 33rd edition of the annual J.P. Morgan Healthcare Conference which will be held from 12 to 16 January 2015 in San Francisco. 

The J.P. Morgan Healthcare conference is the largest and most informative healthcare investment conference. This conference attracts a broad range of US-based analysts and institutional investors. 

Cardio3 BioSciences will meet with potential investors and explain to them its on-going development programs and strategic vision for the future.

Patrick Jeanmart, CFO of Cardio3 BioSciences, commented: “2014 was rich in events for our company. We made significant progress in the European Phase III clinical trial of C-Cure® and our strategic development was strengthened by an enlarged collaboration with Mayo Clinic and the acquisition of CorQuest Inc. The J.P. Morgan Healthcare Conference is an excellent opportunity to present Cardio3 BioSciences’ potential and strategic vision to new investors in view of increasing the visibility and the awareness of our Company towards large institutional investors.”

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Corporate, Non-regulated

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good functioning of our website. You can find out more information about the cookies we use by visiting our Cookie Policy. I acceptI refuseCookie Policy